

This report presents the recommendations of the thirty-sixth WHO Expert Committee on Drug Dependence (ECDD). The ECDD is responsible for the assessment of therapeutic usefulness, the liability to abuse and dependence and the public health and social harm of each substance under review. After receiving the advice from the Expert Committee to schedule or to amend the scheduling status of a substance, the Director-General of WHO will as appropriate, communicate the recommendations to the United Nations. The report summarizes the review of 26 substances and the Committee's recommendations for scheduling under the international drug control conventions. The report also contains updates from international bodies concerned with controlled substances, a summary of the follow-up on recommendations made at the previous Committee meeting and a summary of the discussion on improving data collection and evidence for prioritization and substance evaluation, in particular for new psychoactive substances. Issues identified for consideration at future Expert Committee meetings are also listed.

# WHO Expert Committee on Drug Dependence

Thirty-sixth report



9 789241 209915

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective — the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int); order on line: <http://www.who.int/bookorders>).

---

## SELECTED WHO PUBLICATIONS OF RELATED INTEREST

---

### **Ensuring balance in national policies on controlled substances: guidance for availability and accessibility of controlled medicines**

World Health Organization Geneva, 2011, ISBN 978 92 4 156417 5 (78 pages)

### **Persisting pain in children package: WHO guidelines on pharmacological treatment of persisting pain in children with medical illnesses**

World Health Organization Geneva, 2011, ISBN 978 92 4 154812 0 (229 pages)

### **WHO Expert Committee on Drug Dependence**

Thirty-fifth report

WHO Technical Report Series, No. 973, 2012, ISBN 978 92 4 120973 1 (27 pages)

### **WHO Expert Committee on Drug Dependence**

Thirty-fourth report

WHO Technical Report Series, No. 942, 2006, ISBN 978 92 4 120942 7 (27 pages)

### **WHO Expert Committee on Drug Dependence**

Thirty-third report

WHO Technical Report Series, No. 915, 2003, ISBN 978 92 4 120915 1 (25 pages)

### **WHO Expert Committee on Drug Dependence**

Thirty-second report

WHO Technical Report Series, No. 903, 2001, ISBN 978 92 4 120903 8 (26 pages)

### **WHO Expert Committee on Drug Dependence**

Thirty-first report

WHO Technical Report Series, No. 887, 1999, ISBN 978 92 4 120887 1 (28 pages)

### **The Selection and Use of Essential Medicines**

Report of the WHO Expert Committee, 2013 (including the 18th WHO Model List of Essential Medicines and the 4th WHO Model List of Essential Medicines for Children)

WHO Technical Report Series, No. 985, 2014, ISBN 978 92 4 120985 4 (219 pages)

### **Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence**

World Health Organization, Geneva, 2009, ISBN 978 92 4 154754 3 (129 pages)

---

Further information on these and other WHO publications can be obtained from :  
 WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland  
 (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int); order on line:  
<http://www.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s  
9 9 1

# WHO Expert Committee on Drug Dependence

---

Thirty-sixth report

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health  
Organization**

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on Drug Dependence : thirty-sixth report.

(WHO technical report series ; no. 991)

1.Psychotropic Drugs - classification. 2.Drug Evaluation. 3.Drug and Narcotic Control. 4.Drugs, Essential – supply and distribution. 5.International Cooperation. I.World Health Organization. II.WHO Expert Committee on Drug Dependence. Meeting (36th: 2014: Geneva, Switzerland). III.Series.

ISBN 978 92 4 120991 5

(NLM classification: WM 270)

ISBN (PDF) 978 92 4 069383 8

ISSN 0512-3054

**©World Health Organization 2015**

All rights reserved. Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Layout: L'IV Com Sàrl, Villars-sous-Yens, Switzerland  
Printed in Italy

# Contents

<b>WHO Expert Committee on Drug Dependence</b>	v
<b>Abbreviations</b>	viii
<b>Introduction</b>	1
<b>1. Follow-up on recommendations made by the ECDD at its thirty-fifth meeting</b>	4
1.1 Gamma hydroxybutyric acid (GHB)	4
1.2 Dronabinol (INN)	4
1.3 Ketamine (INN)	5
1.4 ECDD Secretariat follow-up on other matters	5
<b>2. Work of international bodies concerned with controlled substances</b>	7
2.1 Update from the International Narcotics Control Board	7
2.2 Update from the United Nations Office on Drugs and Crime	7
2.3 Update from WHO	8
2.4 Challenges in assessing new psychoactive substances	9
<b>3. Critical review of psychoactive substances</b>	11
3.1 <i>N</i> -Benzylpiperazine (BZP)	11
3.2 Tapentadol (INN)	13
3.3 Gamma-butyrolactone (GBL)	14
3.4 1,4-Butanediol (1,4-BD)	16
3.5 JWH-018	17
3.6 JWH-073	19
3.7 AM-2201	20
3.8 UR-144	21
3.9 APINACA (AKB-48)	23
3.10 RCS-4	24
3.11 JWH-250	25
3.12 Mephedrone	26
3.13 3,4-Methylenedioxypyrovalerone (MDPV)	28
3.14 Methylone (BK-MDMA)	29
3.15 4-Methylethcathinone (4-MEC)	30
3.16 4-Fluoromethcathinone (fephedrone; 4-FMC)	32
3.17 25B-NBOMe	33
3.18 25C-NBOMe	34
3.19 25I-NBOMe	35
3.20 Alpha-methyltryptamine (AMT)	37
3.21 AH-7921	38
3.22 Methoxetamine	39
3.23 Methiopropamine (MPA)	40
3.24 Ketamine (INN)	42

<b>4. Pre-review of psychoactive substances</b>	44
4.1  Lisdexamfetamine (INN)	44
4.2  Tramadol (INN)	45
<b>5. Information on exemptions</b>	47
<b>6. Other matters</b>	48
6.1  Improving data collection and evidence base for substance evaluation in cooperation with other agencies	48
6.2  Planning evaluation of cannabis	48
6.3  Future agenda items	49
<b>Acknowledgements</b>	50
<b>References</b>	51

# WHO Expert Committee on Drug Dependence

Geneva, Switzerland, 16–20 June 2014

## Members<sup>1</sup>

Dr J. Al-Fannah, Clinical Pharmacist, Department of Pharmacy, Royal Hospital Muscat, Sultanate of Oman

Professor M.S. Bourin, Psychopharmacologist, researcher and trainer, Laboratoire de Pharmacologie, Faculté de Médecine, Nantes, France

Dr B. Brands, Senior Science Adviser and Senior Scientist, Health Canada; Affiliate Scientist, Centre for Addiction and Mental Health, Toronto, Canada; Assistant Professor, Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada (*Chair*)

Professor R. Buitrago, Clinical Pharmacist, Vice-dean, Departamento de Farmacia Clínica, Facultad de Farmacia, Universidad de Panamá, Panama

Dr A. Dodoo, Acting Director, Centre for Tropical Clinical Pharmacology and Therapeutics, College of Health Sciences, Ghana Medical School, Accra, Ghana

Dr S.P. Elliott, Forensic Toxicologist and Managing Director, ROAR Forensics, Malvern, England (*Rapporteur*)

Ms G. Mahlangu, Director, Medicines Control Authority, Adverse Drug Reactions and Medicines Review Committee, Harare, Zimbabwe

Dr P.S. Noveria, General Practitioner, Drug Dependence Hospital (RSKO), Jakarta, Indonesia

Dr E.J.M. Pennings, Associate Professor of Forensic Toxicology, The Maastricht Forensic Institute, Maastricht University, Maastricht, The Netherlands

Dr E. Razaghi, Associate Professor of Psychiatry, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran (*Co-chair*)

Professor J.B. Saunders, Professor and Consultant Physician in Internal Medicine and Addiction Medicine, University of Sydney, Sydney, New South Wales, Australia

Dr L. Slamet, Technical Adviser, National Agency for Drug and Food Control, Jakarta, Indonesia

Professor T. Suzuki, Professor, Department of Toxicology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Tokyo, Japan

<sup>1</sup> Unable to attend: Mrs L. De Lima, Executive Director, International Association for Hospice and Palliative Care, Houston, TX, USA; Dr C. Nath, Chief Scientist, Division of Toxicology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.

Professor J. White, Professor of Pharmacology and Head, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

## Representatives from other organizations

*International Narcotics Control Board (INCB)*

Mrs E. Fernandez Santis, Chief, Psychotropics Control Section, INCB, Vienna, Austria

Professor S. Suryawati, Member of INCB, Vienna, Austria and Head, Division of Medicine Policy and Management, Department of Pharmacology and Therapeutics, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia

*United Nations Office on Drugs and Crime (UNODC)*

Dr J. Tettey, Chief, Laboratory and Scientific Section, Research and Trend Analysis Branch, Division for Policy Analysis and Public Affairs, UNODC, Vienna, Austria

*European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)*

Dr M. Evans-Brown, Scientific Analyst, Action on New Drugs, EMCDDA, Lisbon, Portugal

## Secretariat

Professor P.M. Beardsley, Professor of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA (*Temporary Adviser*)

Dr W. Best, Senior Inspector, Healthcare Inspectorate, The Hague, The Netherlands (*Temporary Adviser*)

Dr S.D. Brandt, Reader in Bioactive Drug Chemistry, School of Pharmacy and Biomolecular Sciences, John Moores University, Liverpool, England (*Temporary Adviser*)

Mr C. de Joncheere, Director, Department of Essential Medicines and Health

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report/>